Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02920008
Other study ID # SGI-110-06
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 16, 2017
Est. completion date June 1, 2020

Study information

Verified date May 2023
Source Astex Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multicenter, randomized, open-label, parallel-group study of guadecitabine vs treatment choice (TC). Participants will be randomly assigned in a 1:1 ratio to either guadecitabine or TC. TC options include the 8 high or low intensity, locally available regimens below; or Best supportive Care (BSC) alone: - High intensity (intermediate or high dose cytarabine [HiDAC]; mitoxantrone, etoposide, and cytarabine [MEC]; or fludarabine, cytarabine, granulocyte colony stimulating factor [G-CSF], +/- idarubicin [FLAG/FLAG-Ida]). - Low intensity (low dose cytarabine [LDAC], decitabine, or azacitidine). - BSC.


Description:

This Phase 3, randomized, open-label, parallel-group multicenter study of the efficacy and safety of guadecitabine in adults with previously treated acute myeloid leukemia (AML) will be conducted in approximately 20 countries. There will be a 14-day screening period, a treatment period, a safety follow-up visit, and a long-term follow-up period. The study is expected to last approximately 2 years. Duration of individual participant participation will vary, and participants may continue to receive treatment for as long as they continue to benefit. Approximately 404 participants from approximately 100 study centers will be randomly assigned to either guadecitabine or treatment choice (TC) in a 1:1 ratio (approximately 202 participants per group). TC is as follows: - High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida). - Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine. - Best Supportive Care (BSC). Guadecitabine will be given subcutaneous (SC) at a dose of 60 microgram per meter square (mg/m^2) in 28-day cycles. In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. Cycle 2 will be either the 5-day regimen (Days 1-5) or 10-day regimen (Days 1-5 and 8-12) based on assessment of disease response and hematologic recovery at the end of Cycle 1. In subsequent cycles, guadecitabine treatment will be for 5 days only (Days 1-5).


Recruitment information / eligibility

Status Completed
Enrollment 302
Est. completion date June 1, 2020
Est. primary completion date January 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adult participants =18 years of age who are able to understand study procedures, comply with them, and provide written informed consent before any study-specific procedure. 2. History of cytologically or histologically confirmed diagnosis of AML (except acute promyelocytic leukemia) according to the 2008 World Health Organization (WHO) classification (bone marrow [BM] or peripheral blood [PB] blast counts =20%). 3. Performance status (Eastern Cooperative Oncology Group; ECOG) of 0-2. 4. Participants with AML previously treated with initial induction therapy using a standard intensive chemotherapy regimen, including cytarabine and an anthracycline, and who are refractory to initial induction (primary refractory) or in relapse after such initial induction with or without prior HCT. 5. Participants must have either PB or BM blasts =5% at time of randomization. 6. Creatinine clearance or glomerular filtration rate =30 mL/min as estimated by the Cockroft-Gault (C-G) or other medically acceptable formulas, such as MDRD (Modification of Diet in Renal Disease) or CKD-EPI (the Chronic Kidney Disease Epidemiology Collaboration). 7. Women of child-bearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening. Women of child-bearing potential and men with female partners of child-bearing potential must agree to practice 2 highly effective contraceptive measures of birth control and must agree not to become pregnant or father a child (a) while receiving treatment of guadecitabine, decitabine, or azacitidine and for at least 3 months after completing treatment and (b) while receiving treatment with high-intensity TC or LDAC and for at least 6 months after completing treatment. Exclusion Criteria: 1. Known clinically active central nervous system (CNS) or extramedullary AML, except leukemia cutis. 2. Participants who are in first relapse after initial induction, if they had a response duration of >12 months from date when first response first documented or if they are good candidates for HCT. 3. BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis). 4. Second malignancy currently requiring active therapy, except breast or prostate cancer stable on or responding to endocrine therapy. 5. Grade 3 or higher Graft Versus Host Disease (GVHD), or GVHD on either a calcineurin inhibitor or prednisone more than 5 mg/day. 6. Prior treatment with guadecitabine for any indication, or more than 2 cycles of prior decitabine or azacitidine. 7. Hypersensitivity to decitabine, guadecitabine, or any of their excipients. 8. Treated with any investigational therapy within 2 weeks of the first dose of study treatment. 9. Total serum bilirubin >2.5 × upper limit of normal (ULN; except for participants with Gilbert's Syndrome for whom direct bilirubin is <2.5 × ULN), or liver cirrhosis, or chronic liver disease Child-Pugh Class B or C. 10. Known active human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals is allowed. 11. Known significant mental illness or other condition such as active alcohol or other substance abuse or addiction that, in the opinion of the investigator, predisposes the participant to high risk of noncompliance with the protocol. 12. Refractory congestive heart failure unresponsive to medical treatment; active infection resistant to all antibiotics; or non-AML-associated pulmonary disease requiring >2 liters per minute (LPM) oxygen, or any other condition that puts the participant at an imminent risk of death. 13. Participants with high PB blasts >50% AND poor ECOG PS of 2.

Study Design


Intervention

Drug:
guadecitabine
In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. In Cycle 2, the guadecitabine dose will be 60 mg/m^2 for either 10 days (Days 1-5 and 8-12) or 5 days (Days 1-5 only) based on assessment of disease response, and hematological recovery by Day =28.
Treatment Choice (TC)
High intensity: intermediate or high dose cytarabine (HiDAC); mitoxantrone, etoposide, and cytarabine (MEC); or fludarabine, cytarabine, G-CSF, +/- idarubicin (FLAG/FLAG-Ida). Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine. Best Supportive Care (BSC).

Locations

Country Name City State
Belgium AZ Sint-Jan Brugge-Oostende AV Brugge
Belgium Cliniques Universitaires Saint-Luc Brussels
Belgium Universitair Ziekenhuis Gent Gent
Canada Tom Baker Cancer Centre Calgary Alberta
Canada University of Alberta Hospital Edmonton Alberta
Canada Hopital Maisonneuve Rosemont Montreal
Canada McGill University Health Centre Montreal Quebec
Canada Princess Margaret Cancer Centre Toronto Ontario
Denmark Aarhus University Hospital Aarhus C
Denmark Rigshospitalet Copenhagen
France Centre Hospitalier de la Côte Basque Bayonne
France Hôpital de la Conception Marseille
France CHRU Montpellier - Saint Eloi Montpellier
France Groupe Hospitalier de la Région de Mulhouse et Sud Alsace Mulhouse
France Hôpital Saint-Louis Paris
France CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque Pessac
France Centre Hospitalier Lyon-Sud Pierre Bénite
France Centre Henri Becquerel Rouen cedex 1
France Institut Universitaire du Cancer de Toulouse - Oncopole Toulouse
Germany Städtisches Klinikum Braunschweig gGmbH Braunschweig
Germany Marien Hospital Düsseldorf GmbH Düsseldorf
Germany Universitätsklinikum Halle (Saale) Halle
Germany Universitätsklinikum Schleswig-Holstein Kiel
Germany Universitätsklinikum Leipzig Leipzig Sachsen
Germany Medizinischen Fakultät Mannheim der Universität Heidelberg Mannheim
Germany Klinikum der Universität München Muenchen
Germany Universitätsklinikum Ulm Ulm
Hungary SE ÁOK I. sz. Belgyógyászati Klinika Budapest
Hungary Debreceni Egyetem Klinikai Központ Debrecen
Hungary Somogy Megyei Kaposi Mór Oktató Kórház Kaposvar
Hungary Pecsi Tudomanyegyetem Klinikai Központ Pécs
Hungary Szegedi Tudományegyetem Szeged
Italy IRCCS AOU San Martino - IST Genova
Italy Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano
Italy Ospedale San Raffaele - Milano Milano
Italy A.O.R.N. "A. Cardarelli" Napoli
Italy A.S.U Integrata di Udine - Presidio Ospedaliero Santa Maria della Misericordia Udine
Japan Akita University Hospital Akita-shi
Japan Chugoku Central Hospital Fukuyama-Shi
Japan Tokai University Hospital Isehara-shi
Japan Saitama Medical Center Kawagoe-Shi
Japan Kobe City Medical Center General Hospital Kobe-shi
Japan Japanese Red Cross Kyoto Daini Hospital Kyoto-shi
Japan University Hospital, Kyoto Prefectural University of Medicine Kyoto-shi
Japan Gunmaken Saiseikai Maebashi Hospital Maebashi-shi
Japan Nagasaki University Hospital Nagasaki-shi
Japan The Japanese Red Cross Nagasaki Genbaku Hospital Nagasaki-Shi
Japan Kindai University Hospital Osakasayama-Shi
Japan Saga University Hospital Saga-shi
Japan NTT Medical Center Tokyo Shinagawa-Ku
Japan Shizuoka Cancer Center Shizuoka
Japan National Hospital Organization Disaster Medical Center Tachikawa-Shi
Japan Yamagata University Hospital Yamagata-Shi
Japan University of Fukui Hospital Yoshida-Gun
Korea, Republic of Pusan National University Hospital Busan
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Severance Hospital Seoul
Korea, Republic of The Catholic University of Korea, Seoul St. Mary's Hospital Seoul
Korea, Republic of Ulsan University Hospital (UUH) Ulsan
Poland Instytut Hematologii i Transfuzjologi Warszawa
Spain Hospital Clínic de Barcelona Barcelona
Spain Hospital de la Santa Creu i Sant Pau Barcelona
Spain Hospital Duran i Reynals Barcelona
Spain Vall d'Hebron Institut d'Oncologia Barcelona
Spain Hospital San Pedro de Alcántara Cáceres
Spain Hospital Universitario Reina Sofía Córdoba
Spain Hospital General Universitario Gregorio Marañón Madrid
Spain Hospital Universitario Central de Asturias Oviedo
Spain Hospital Universitario Virgen del Rocío Sevilla
Spain Hospital Universitari i Politècnic La Fe Valencia
Spain Hospital Universitario Dr. Peset Valencia
Sweden Sahlgrenska University Hospital Göteborg
Ukraine Khmelnytskyi Regional Hospital Khmelnytskyi
Ukraine Poltava Regional Clinical Hospital named after M. V. Sklifosovskoho Poltava
United Kingdom Heart of England NHS Foundation Trust - Heartlands Hospital Birmingham
United Kingdom University Hospitals Bristol NHS Foundation Trust - Bristol Haematology and Oncology Centre Bristol
United Kingdom East Kent Hospitals University NHS Foundation Trust - Kent and Canterbury Hospital Canterbury
United Kingdom St. James's University Hospital Leeds
United States University of New Mexico School of Medicine Albuquerque New Mexico
United States Roswell Park Cancer Institute Buffalo New York
United States The University of Chicago Medical Center Chicago Illinois
United States Baylor Research Institute Dallas Texas
United States Duke Cancer Institute Durham North Carolina
United States John Theurer Cancer Center at Hackensack University Medical Center Hackensack New Jersey
United States MD Anderson Cancer Center Houston Texas
United States Franciscan Research Center Indianapolis Indiana
United States University of Southern California Los Angeles California
United States West Virginia University Hospitals, Inc. Morgantown West Virginia
United States Vanderbilt University Medical Center Nashville Tennessee
United States Weill Cornell Medical College New York New York
United States University of Oklahoma Medical Center Oklahoma City Oklahoma
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania
United States Temple University Hospital Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Astex Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  Denmark,  France,  Germany,  Hungary,  Italy,  Japan,  Korea, Republic of,  Poland,  Spain,  Sweden,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival Overall survival is defined as number of days from day of randomization to date of death, regardless of cause. From the date of randomization until the date of death, or approximately 34 months
Secondary Event-Free Survival Event-free survival is defined as number of days from randomization to earliest date of treatment discontinuation (for reasons other than initiation of hematopoietic cell transplant [HCT]), start of alternative anti-leukemia therapy (except HCT), or death. From the date of randomization until the date of death, or approximately 38 months
Secondary Long-Term Survival Survival rate at 1 year after randomization; participants were also followed to estimate 2-year survival rate. Up to approximately 38 months
Secondary Number of Days Alive and Out of the Hospital (NDAOH) Number of days participants alive and out of hospital during first 6 months of the study. 6 months
Secondary Transfusion Independence Rate Number of participants without red blood cells (RBC) or platelet transfusion for any 8-week period after treatment divided by total number of participants in efficacy analysis. Baseline up to approximately 38 months
Secondary Complete Response Rate The Complete response (CR) rate based on modified International Working Group (IWG) 2003 AML Response Criteria was calculated as the number of participants with a best response of CR divided by the total number of participants included in the efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is absolute neutrophil count (ANC) =1000/µL, platelets =100,000/µL, independence from red blood cells (RBC) and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells. Baseline to end of treatment, or approximately 38 months
Secondary Combined Complete Response and Complete Response With Partial Hematologic Recovery Rate The combined CR and CR with partial hematologic recovery rate based on modified International Working Group (IWG) 2003 AML Response Criteria was calculated as number of participants with CR and CR with partial hematologic recovery divided by the total number of participants included in the efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is absolute neutrophil count (ANC) =1000/µL, platelets =100,000/µL, independence from red blood cells (RBC) and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells. Baseline to end of treatment, or approximately 38 months
Secondary Composite Complete Response Rate Composite complete response rate based on modified IWG 2003 AML Response Criteria defined as number of participants with best response of CR, CR with incomplete platelet recovery (CRp), or CR with incomplete blood count recovery (CRi) divided by total number of participants in efficacy analysis. CR as per modified 2003 IWG AML Response Criteria is ANC =1000/µL, platelets =100,000/µL, independence from RBC and platelet transfusions over the past week, no leukemic blasts in peripheral blood and bone marrow should contain less than 5% blast cells. CRp is defined as ANC =1000/µL, Platelets <100,000/µL, independence from RBC transfusions over the past week, no leukemic blasts and bone marrow should contain less than 5% blast cells. CRi is defined as ANC <1000/µL, no leukemic blasts and bone marrow should contain less than 5% blast cells. Baseline to end of treatment, or approximately 38 months
Secondary Hematopoietic Cell Transplant (HCT) Rate Number of participants who received HCT after randomization divided by total number of participants in efficacy analysis. Baseline to long term follow-up or approximately 38 months
Secondary Duration of Complete Response (CR) + CR With Partial Hematologic Recovery (CRh) The time from first CR or CRh to time of relapse (the date of the earliest of the following 3 events):
relapse (defined as the earliest time point whereby BM assessment or PB assessment by the investigator indicate relapse/disease progression due to confirmed reappearance of leukemic blasts in PB or =5% leukemic blasts in BM, or clinical progression determined by the investigator),
start of alternative therapy (except HCT) or
death.
Baseline to end of treatment, or approximately 38 months
Secondary Change From Baseline in EuroQoL-5 Dimension 5 Level (EQ-5D-5L) Index Scores Index score is calculated based on 5-level version of the EQ-5D descriptive system using the value set for England.
The range of index score is from -0.281 (for the worst health state, score of 5 for all categories) to 1 (for the best health state, score of 1 for all categories).
Baseline to 6 months
Secondary Change in EQ-5D-5L Visual Analogue Scale (VAS) Score VAS score is obtained using vertical 20-cm visual analogue scale with the top value of 100 labelled as 'the best health you can imagine' and the bottom value of 0 labelled as 'the worst health you can imagine'. Baseline to 6 months
Secondary Percentage of Participants With Adverse Events (AEs) An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including a clinically significant abnormal finding in laboratory tests or other diagnostic procedures), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. From first dose until 30 days after the last dose of study drug, or approximately 38 months
Secondary All-Cause Mortality All-cause mortality in the first 30 days and first 60 days after the start of treatment divided by the total number of participants receiving at least one dose of study treatment. From the first dose until 60 days after the first dose of study drug
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2